University of Minnesota Medical Center welcomes new providers to the Liver Clinic team. Transplant hepatologist, Nicholas Lim, MD, completed his fellowship training at Columbia University. His research interests include quality of care issues for patients with liver disease and those undergoing liver transplantation. Gastroenterologist Amar Mahgoub, MD, completed his fellowship training at University of Minnesota. His research interests include fatty liver disease and changes in the human gut microbiome. Both providers offer a high level of expertise in care for patients with liver disease, with a special emphasis on preserving patients’ autonomy and well-being.
The Liver Clinic at University of Minnesota Medical Center is currently participating in a longitudinal cohort study designed to evaluate the realworld uses and outcomes of directactiving antiviral-containing regimens used in the treatment of chronic hepatitis C virus infections. The study, which involves 38 academic and 15 community medical centers in the United States, Germany, and Canada, is observational only. Patients in the study receive HCV therapy selected and administered by their treating physicians, according to local standards of care.
Patient enrollment in a study of treatments for hepatitis C virus genotype 1a or 1b infection has now opened. Patients with or without cirrhosis are eligible. The Prioritize study will compare the safety and efficacy of 3 direct-acting antiviral medication regimens: sofosbuvir with ledipasvir; the regimen of paritaprevir, ritonavir, ombitasvir, dasabuvir, ribavirin (for genotype 1a only); and the grazoprevir and elbasvir regimen. The study will also seek to track treatment adherence, out-of-pocket costs, and post-treatment progression and regression of liver disease. HCV genotype 1 infection accounts for approximately 70% to 75% of all HCV infections in the United States and has historically been difficult to treat.
New direct-acting antivirals show promise in the treatment of recurring hepatitis C infections. A leading cause of liver failure and transplant, HCV recurs in 80% of transplant patients with the disease.Continue reading
A 54-year-old man with very severe HCV infection recurring 9 months post-liver transplant was successfully treated in a clinical trial of a direct-acting antiviral combination therapy.Continue reading